hims & hers

We're thrilled to share some exciting results from our Q1 2025 earnings: ✔ Revenue of $586 million, up 111% YoY ✔ Subscribers grew to 2.4 million, up 38% YoY ✔ 60% of our subscribers are opting for personalized solutions on the platform What's more, alongside our Q1 results, we shared something even more important: our vision for the future. A roadmap for what this company can become, and how we plan to get there. We’ve set a bold target: $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030. Tap to read more from our CEO: https://bit.ly/3Sm0Kjz

Our new data reveals that among those who participated in a 6 month check-in, 75% stayed on their weight loss treatment plans. This is a powerful signal of real-world trust and clinical success. 🔗 See the details of the analysis: https://bit.ly/4749rYk *𝘊𝘰𝘮𝘱𝘰𝘶𝘯𝘥𝘦𝘥 𝘥𝘳𝘶𝘨𝘴 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘰𝘳 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘦𝘥 𝘧𝘰𝘳 𝘴𝘢𝘧𝘦𝘵𝘺, 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦𝘯𝘦𝘴𝘴, 𝘰𝘳 𝘲𝘶𝘢𝘭𝘪𝘵𝘺 𝘣𝘺 𝘵𝘩𝘦 𝘍𝘋𝘈. 𝘉𝘢𝘴𝘦𝘥 𝘰𝘯 𝘴𝘦𝘭𝘧-𝘳𝘦𝘱𝘰𝘳𝘵𝘦𝘥 𝘥𝘢𝘵𝘢 𝘢𝘴 𝘰𝘧 𝘑𝘶𝘯𝘦 2025 𝘧𝘳𝘰𝘮 13,458 𝘏𝘪𝘮𝘴 & 𝘏𝘦𝘳𝘴 𝘤𝘶𝘴𝘵𝘰𝘮𝘦𝘳𝘴, 6 𝘮𝘰𝘯𝘵𝘩𝘴 𝘪𝘯 𝘵𝘦𝘯𝘶𝘳𝘦 𝘰𝘯 𝘢 𝘱𝘦𝘳𝘴𝘰𝘯𝘢𝘭𝘪𝘻𝘦𝘥 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘱𝘭𝘢𝘯 𝘪𝘯𝘤𝘭𝘶𝘥𝘪𝘯𝘨 𝘤𝘰𝘮𝘱𝘰𝘶𝘯𝘥𝘦𝘥 𝘎𝘓𝘗-1 𝘪𝘯𝘫𝘦𝘤𝘵𝘪𝘰𝘯𝘴, 𝘢𝘭𝘰𝘯𝘨 𝘸𝘪𝘵𝘩 𝘢 𝘳𝘦𝘥𝘶𝘤𝘦𝘥-𝘤𝘢𝘭𝘰𝘳𝘪𝘦 𝘥𝘪𝘦𝘵 𝘢𝘯𝘥 𝘦𝘹𝘦𝘳𝘤𝘪𝘴𝘦. 𝘏𝘪𝘮𝘴 & 𝘏𝘦𝘳𝘴, 𝘛𝘩𝘦 1-𝘠𝘦𝘢𝘳 𝘑𝘰𝘶𝘳𝘯𝘦𝘺 𝘰𝘧 𝘏𝘪𝘮𝘴 & 𝘏𝘦𝘳𝘴 𝘞𝘦𝘪𝘨𝘩𝘵 𝘓𝘰𝘴𝘴 𝘊𝘶𝘴𝘵𝘰𝘮𝘦𝘳𝘴, 𝘞𝘩𝘪𝘵𝘦 𝘗𝘢𝘱𝘦𝘳, 2025.

It’s been more than a year since weight loss treatment plans were launched through Hims & Hers—and we’re proud of the experience we’ve built. Recently, we released new data showing that our digital-first approach to personalized weight loss is driving meaningful, sustainable results, laying the groundwork for lasting success. 🔗 See the results of the analysis: https://bit.ly/4749rYk *𝘊𝘰𝘮𝘱𝘰𝘶𝘯𝘥𝘦𝘥 𝘥𝘳𝘶𝘨𝘴 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘰𝘳 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘦𝘥 𝘧𝘰𝘳 𝘴𝘢𝘧𝘦𝘵𝘺, 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦𝘯𝘦𝘴𝘴, 𝘰𝘳 𝘲𝘶𝘢𝘭𝘪𝘵𝘺 𝘣𝘺 𝘵𝘩𝘦 𝘍𝘋𝘈. 𝘉𝘢𝘴𝘦𝘥 𝘰𝘯 𝘴𝘦𝘭𝘧-𝘳𝘦𝘱𝘰𝘳𝘵𝘦𝘥 𝘥𝘢𝘵𝘢 𝘢𝘴 𝘰𝘧 𝘑𝘶𝘯𝘦 2025 𝘧𝘳𝘰𝘮 13,458 𝘏𝘪𝘮𝘴 & 𝘏𝘦𝘳𝘴 𝘤𝘶𝘴𝘵𝘰𝘮𝘦𝘳𝘴, 6 𝘮𝘰𝘯𝘵𝘩𝘴 𝘪𝘯 𝘵𝘦𝘯𝘶𝘳𝘦 𝘰𝘯 𝘢 𝘱𝘦𝘳𝘴𝘰𝘯𝘢𝘭𝘪𝘻𝘦𝘥 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘱𝘭𝘢𝘯 𝘪𝘯𝘤𝘭𝘶𝘥𝘪𝘯𝘨 𝘤𝘰𝘮𝘱𝘰𝘶𝘯𝘥𝘦𝘥 𝘎𝘓𝘗-1 𝘪𝘯𝘫𝘦𝘤𝘵𝘪𝘰𝘯𝘴, 𝘢𝘭𝘰𝘯𝘨 𝘸𝘪𝘵𝘩 𝘢 𝘳𝘦𝘥𝘶𝘤𝘦𝘥-𝘤𝘢𝘭𝘰𝘳𝘪𝘦 𝘥𝘪𝘦𝘵 𝘢𝘯𝘥 𝘦𝘹𝘦𝘳𝘤𝘪𝘴𝘦. 𝘏𝘪𝘮𝘴 & 𝘏𝘦𝘳𝘴, 𝘛𝘩𝘦 1-𝘠𝘦𝘢𝘳 𝘑𝘰𝘶𝘳𝘯𝘦𝘺 𝘰𝘧 𝘏𝘪𝘮𝘴 & 𝘏𝘦𝘳𝘴 𝘞𝘦𝘪𝘨𝘩𝘵 𝘓𝘰𝘴𝘴 𝘊𝘶𝘴𝘵𝘰𝘮𝘦𝘳𝘴, 𝘞𝘩𝘪𝘵𝘦 𝘗𝘢𝘱𝘦𝘳, 2025.

🚨New data alert: Today, we released the first U.S. research of its kind on compounded GLP-1 treatments—and the results reinforce the impact of our personalized, digital-first weight loss model. Our approach puts the individual at the center of care, and the outcomes speak for themselves: 🔹 75% of customers stay on a plan within 6 months 🔹 Low incidence of reported side effects—just 4.5% intolerable 🔹 97% reported improved overall health 🔹 20.9 lbs average weight loss at 6 months We’re proud to combine clinical rigor with innovation to create a scalable, human-centered model for sustainable weight management. 📄 Read the full white paper to explore the data and our model for long-term success: https://bit.ly/4749rYk #DigitalHealth #GLP1 #ObesityCare #HealthTech #ClinicalInnovation #HimsAndHers 𝘏𝘪𝘮𝘴 & 𝘏𝘦𝘳𝘴 𝘐𝘯𝘵𝘦𝘳𝘯𝘢𝘭 𝘋𝘢𝘵𝘢, 𝘢𝘴 𝘰𝘧 𝘑𝘶𝘯𝘦 30, 2025. 𝘊𝘶𝘴𝘵𝘰𝘮𝘦𝘳𝘴' 𝘳𝘦𝘴𝘶𝘭𝘵𝘴 𝘩𝘢𝘷𝘦 𝘯𝘰𝘵 𝘣𝘦𝘦𝘯 𝘪𝘯𝘥𝘦𝘱𝘦𝘯𝘥𝘦𝘯𝘵𝘭𝘺 𝘷𝘦𝘳𝘪𝘧𝘪𝘦𝘥. 𝘐𝘯𝘥𝘪𝘷𝘪𝘥𝘶𝘢𝘭 𝘳𝘦𝘴𝘶𝘭𝘵𝘴 𝘮𝘢𝘺 𝘷𝘢𝘳𝘺. 𝘋𝘳. 𝘗𝘳𝘪𝘮𝘢𝘤𝘬 𝘪𝘴 𝘢 𝘳𝘦𝘢𝘭 𝘥𝘰𝘤𝘵𝘰𝘳, 𝘣𝘶𝘵 𝘩𝘦’𝘴 𝘯𝘰𝘵 𝘺𝘰𝘶𝘳 𝘥𝘰𝘤𝘵𝘰𝘳, 𝘢𝘯𝘥 𝘩𝘪𝘴 𝘦𝘹𝘱𝘦𝘳𝘵𝘪𝘴𝘦 𝘴𝘩𝘰𝘶𝘭𝘥 𝘯𝘰𝘵 𝘣𝘦 𝘵𝘢𝘬𝘦𝘯 𝘢𝘴 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦. 𝘈𝘭𝘸𝘢𝘺𝘴 𝘤𝘰𝘯𝘴𝘶𝘭𝘵 𝘢 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘳 𝘣𝘦𝘧𝘰𝘳𝘦 𝘮𝘢𝘬𝘪𝘯𝘨 𝘩𝘦𝘢𝘭𝘵𝘩 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯𝘴.

#HIRING 🚨 We’re looking for a Director, Pharma Technology Transfer (Tablets) to join the team! This person provides strategic leadership and technical expertise in the transfer of pharmaceutical manufacturing processes and technologies from one site to another (internal or external). Candidates should have at least 10 years of experience in pharmaceutical manufacturing or technology transfer, preferably with tablet manufacturing experience, and a minimum of 5 years in a leadership role. Learn more about the role: https://bit.ly/4nWHRSM #telehealth #telemedicine #jobopening

#HIRING 🚀 We’re looking for a Manager, Pharma Technology Transfer (Tablets) to join the team! This person will lead and manage the successful transfer of pharmaceutical tablet manufacturing processes between development and manufacturing sites, and/or between manufacturing sites, ensuring consistent product quality, efficiency, and regulatory compliance. Learn more about the role: https://bit.ly/4nVOtRv #telehealth #telemedicine #jobopening

Our own Dr. Craig Primack spoke with Athletech News about our comprehensive approach to care and the critical role that personalization plays in driving lasting, meaningful outcomes. 📰 Read more: https://bit.ly/46bEAc1 #Himsandhers #WeightLoss #Telehealth #HealthInnovation #Personalization

Obesity is a complex, chronic disease influenced by many factors. As Dr. Craig Primack, SVP of Weight Loss for Hims, explains, personalization helps ensure everyone has the best chance at a sustainable treatment regimen that they're likely to stick to and achieve lasting results on. Learn more from Dr. Primack on personalized treatment in obesity care: https://bit.ly/46I6Fru 𝘋𝘳. 𝘗𝘳𝘪𝘮𝘢𝘤𝘬 𝘪𝘴 𝘢 𝘳𝘦𝘢𝘭 𝘥𝘰𝘤𝘵𝘰𝘳, 𝘣𝘶𝘵 𝘵𝘩𝘦𝘺'𝘳𝘦 𝘯𝘰𝘵 𝘺𝘰𝘶𝘳 𝘥𝘰𝘤𝘵𝘰𝘳 𝘢𝘯𝘥 𝘵𝘩𝘦𝘪𝘳 𝘦𝘹𝘱𝘦𝘳𝘵𝘪𝘴𝘦 𝘴𝘩𝘰𝘶𝘭𝘥 𝘯𝘰𝘵 𝘣𝘦 𝘵𝘢𝘬𝘦𝘯 𝘢𝘴 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦. 𝘈𝘭𝘸𝘢𝘺𝘴 𝘤𝘰𝘯𝘴𝘶𝘭𝘵 𝘢 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘳 𝘣𝘦𝘧𝘰𝘳𝘦 𝘮𝘢𝘬𝘪𝘯𝘨 𝘩𝘦𝘢𝘭𝘵𝘩 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯𝘴.

#HIRING 🚀 This is an exciting opportunity to expand and elevate the Paid Search function at Hims & Hers. As the Senior Manager, Paid Search, you will not only drive growth within your own category but also develop and scale innovative approaches that impact our broader paid search strategy across multiple product lines. Learn more about the role: https://bit.ly/40HwuUS #telehealth #telemedicine #jobopening #telehealthjobs

#HIRING 🚨We are looking for a physician (MD/DO) who has experience reviewing consumer-facing content for medical accuracy. Your role would be to review the articles and provide feedback to editors and writers. This role is for an Independent Contractor who will provide temporary services to Hims & Hers and will be paid on invoice (1099). Learn more about the role: https://bit.ly/44aEKPr #telehealth #telemedicine #telehealthjobs #jobopening